---
title: "Celldex Therap | 10-K: FY2025 Revenue: USD 1.545 M"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276938480.md"
datetime: "2026-02-25T21:12:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276938480.md)
  - [en](https://longbridge.com/en/news/276938480.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276938480.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/276938480.md) | [繁體中文](https://longbridge.com/zh-HK/news/276938480.md)


# Celldex Therap | 10-K: FY2025 Revenue: USD 1.545 M

Revenue: As of FY2025, the actual value is USD 1.545 M.

EPS: As of FY2025, the actual value is USD -3.9, missing the estimate of USD -3.6736.

EBIT: As of FY2025, the actual value is USD -287.37 M.

#### Overall Company Financial Performance

##### Net Loss

Celldex Therapeutics, Inc. reported a net loss of - $258.8 million in 2025, - $157.9 million in 2024, and - $141.4 million in 2023.

##### Operating Loss

The company’s operating loss was - $287.4 million in 2025, - $195.1 million in 2024, and - $154.5 million in 2023.

##### Total Revenues

Total revenues for Celldex Therapeutics, Inc. were $1.5 million in 2025, $7.0 million in 2024, and $6.9 million in 2023.

##### General and Administrative Expenses

General and administrative expenses amounted to $43.8 million in 2025, representing a 14% increase from 2024, and $38.5 million in 2024, a 25% increase from 2023, with 2023 expenses at $30.9 million.

##### Litigation Settlement Related Loss

A litigation settlement related loss of $12.5 million was recorded in 2023, due to a milestone payment under the Settlement Agreement with SRS.

##### Investment and Other Income, Net

Investment and other income, net, was $28.6 million in 2025, a 23% decrease from 2024; $37.2 million in 2024, a 184% increase from 2023; and $13.1 million in 2023.

##### Liquidity

As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $518.6 million.

##### Cash Flow from Operating Activities

Cash flow from operating activities was - $210.9 million in 2025, - $157.8 million in 2024, and - $107.3 million in 2023.

##### Cash Flow from Investing Activities

Investing activities provided $209.1 million in 2025, used - $290.1 million in 2024, and used - $105.8 million in 2023.

##### Cash Flow from Financing Activities

Financing activities provided $2.4 million in 2025, $441.4 million in 2024, and $218.5 million in 2023.

##### Net Proceeds from Stock Issuances

Net proceeds from stock issuances included $432.3 million from an underwritten public offering in 2024 and $216.2 million from an underwritten public offering in 2023.

#### Research and Development Expenses by Program

##### Total Research and Development Expense

Total research and development expense was $245.1 million in 2025, a 50% increase from 2024; $163.6 million in 2024, a 39% increase from 2023; and $118.0 million in 2023.

##### Barzolvolimab/Anti-KIT Program

Expenses for the Barzolvolimab/Anti-KIT Program were $198.3 million in 2025, $123.8 million in 2024, and $79.9 million in 2023.

##### CDX-622 Program

The CDX-622 Program incurred expenses of $19.0 million in 2025, $17.3 million in 2024, and $16.3 million in 2023.

##### Other Programs

Other programs had expenses of $27.8 million in 2025, $22.5 million in 2024, and $21.8 million in 2023.

#### Outlook and Guidance

Celldex Therapeutics, Inc. anticipates a decrease in revenue over the next twelve months due to reduced services under agreements with Rockefeller University, despite potential quarterly fluctuations. The company projects increases in personnel, product development, and general and administrative expenses to support the expanded development of barzolvolimab and commercial planning efforts. While current cash, cash equivalents, and marketable securities are expected to fund operations through 2027, additional capital may be required for long-term liquidity, potentially through dilutive offerings or significant payment obligations.

### 相关股票

- [Celldex Therap (CLDX.US)](https://longbridge.com/zh-CN/quote/CLDX.US.md)

## 相关资讯与研究

- [Celldex Therapeutics Prices $300 Mln Public Offering Of Shares At $29/shr; Stock Down](https://longbridge.com/zh-CN/news/281470537.md)
- [Celldex Announces Pricing of $300 Million Public Offering of Common Stock | CLDX Stock News](https://longbridge.com/zh-CN/news/281449180.md)
- [Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering](https://longbridge.com/zh-CN/news/281522302.md)
- [Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results](https://longbridge.com/zh-CN/news/277110467.md)
- [Sri Lotus Developers Grants 1.2 Million ESOPs Under 2024 Scheme](https://longbridge.com/zh-CN/news/281348606.md)